Articles tagged with Cancer Stem Cells
A novel small-molecule Wnt inhibitor named NCB-0846 has been discovered with potential to eradicate colorectal cancer stem cells. The inhibitor targets the Traf2- and Nck-interacting kinase (TNIK) regulatory component of the Wnt signaling pathway, blocking its signal even in colorectal cancer cells with APC gene mutations.
Researchers identified a critical role for stem cells in cancer formation and found that specific organs are more susceptible due to high wear and tear. The study suggests behaviors like smoking or UV exposure increase the risk of developing cancer.
A large systematic study confirms the crucial contribution of stem cells to cancer origins in different organs. The study reveals that only cells with stem cell activity make cancer, and damage to tissues can 'wake up' sleeping stem cells, increasing cancer risk.
Researchers discovered leukemia stem cells in fatty tissue of obese patients were more resistant to chemotherapy, using fatty acids as their energy source and actively signaling fat for lipolysis. This adaptation could help explain poorer outcomes in obese patients, potentially shedding light on new strategies to target cancer stem cells.
Researchers have discovered a genetic switch, microRNA mirR-125a, that can be used to increase the supply of stem cells from cord blood. This discovery could potentially increase the availability of stem cell transplants for cancer patients with no matching donors.
Researchers have unraveled how pre-leukemic white blood cell precursors become leukemia stem cells by targeting the RNA editing enzyme ADAR1. Inhibiting ADAR1 can counteract its effect on leukemia stem cell self-renewal, potentially reducing cancer progression.
Researchers have discovered that a combination of 5-azacytidine and the HDAC inhibitor butyrate reduces the number of cancer stem cells in breast cancer patients. This targeted approach may improve survival rates and provide a new treatment option for breast cancer.
Scientists at McMaster University have made a breakthrough in understanding the regulation of human blood stem cells, allowing for better control and regeneration. The discovery could lead to more people receiving treatment for life-threatening diseases, reducing healthcare costs and wait times.
A preliminary clinical trial found that an experimental antibody treatment decreased the number of cancer stem cells driving tumor growth in nearly all patients with multiple myeloma. The treatment was tested in 15 newly diagnosed patients and showed promising results, with no serious adverse side effects.
Researchers found that cancer stem cells multiply through the same mechanism used by embryonic stem cells, encouraged by low oxygen levels. The discovery could offer a path to targeting cancer stem cells and reducing their threat in human cancer.
Researchers turned skin cells into cancer-hunting stem cells that destroy brain tumors known as glioblastoma, a breakthrough discovery in medical science. The technique increases survival time by 160-220% and has the potential to offer a new and more effective treatment for the disease.
Researchers at Duke University have discovered that gut inflammation sparks colon cancer, with microRNA miR-34a playing a crucial role in controlling stem cell division. Elevated levels of miR-34a may serve as an early warning system for colon cancer, and its expression could be used to treat late-stage cancer.
Researchers have discovered a molecule that blocks cancer stem cells' ability to survive and replicate. The compound, LF3, targets the Wnt signaling pathway and reduces tumor growth in living animals.
Researchers found that vitamin A can reactivate the HOXA5 protein in cancer cells, eliminating relapse and metastasis. This approach offers a new way to treat colon cancer by targeting a specific biological mechanism.
A Phase I study combining natural killer cells with high-dose chemotherapy and stem cell transplantation showed promising results in treating multiple myeloma. The treatment resulted in no toxicity or graft-versus-host disease, offering a potential new approach for patients.
Researchers at UC San Diego School of Medicine discovered a specific group of proteins decrease, triggering changes in the cancer microenvironment and accelerating growth of therapy-resistant CSCs. A targeted monoclonal antibody treatment effectively impaired CSC regeneration and made them easier to target with existing therapies.
Researchers identified a key protein secreted by basal-like breast cancer cells that supports cancer stem cells. Disrupting this protein or its receptor leads to reduced CSCs and impaired tumor formation.
Min Yu, USC scientist, wins $2.475 million NIH New Innovator Award to target breast cancer stem cells for personalized treatment. Her research aims to identify biomarkers and tailor drugs to individual patients, addressing the significant challenge of metastatic cancer stem cells.
Researchers discovered that cell programs controlling normal mammary gland stem cells differ from those regulating cancer stem cells, which arise in a distinct layer of tissue. This finding could lead to new cancer treatments by targeting the specific differences between normal and cancer cells.
Researchers at Arizona State University have identified a link between chronic inflammation and colon cancer metastasis. The study found that prostaglandin E2 (PGE2) triggers the spread of cancer cells to other organs, leading to increased tumor burden and chemotherapy resistance.
A recent study by Fen Wang and Wallace McKeehan reveals that errors in FGF transmission can activate dormant stem cells, leading to cancer. The research supports the existing theory that cancer is a stem cell disease and holds promise for future cancer therapies.
Researchers at the University of North Carolina have discovered a rare type of stem cell that is immune to radiation damage due to high levels of Sox9. This finding could lead to new ways to protect the gastrointestinal system of cancer patients before treatment, allowing for more aggressive treatments to be used.
Researchers found an enzyme called LSD1 turns off genes required to maintain cancer stem cell properties in glioblastoma. Drugs modifying LSD1 levels could provide a new approach to treating the disease.
A new stem cell population has been identified in the colon that is linked to cancer growth, which could lead to new treatments. The study found that this radiation-resistant stem cell population can give rise to colonic tumors and sustain their growth.
Researchers have designed nanoparticles that specifically target cancer stem cells, which are tough to kill with conventional drugs. The treatment successfully killed CSCs and destroyed tumors in mice tests, with no obvious side effects. This therapy may help overcome the defenses of these hardy cells.
Depletion of naïve T cells from stem cell grafts limits chronic graft-versus host disease by reducing its occurrence and severity. This approach also results in generally responsive acute GVHD to corticosteroid therapy, supporting it as a potential treatment option.
Researchers found that silibinin from milk thistle significantly slowed the growth of colorectal cancer stem cells in mice, reducing tumor size and metabolism. Re-injecting these cancer stem cells into new mice showed a loss of their potential to form aggressive tumors even without silibinin exposure.
Researchers at Moffitt Cancer Center have discovered a novel mechanism controlling lung cancer stem cell growth, suggesting that targeting YAP1 protein could lead to new therapeutic targets. The study found that YAP1 interacts with OCT4 and SOX2 proteins, regulating stem cell self-renewal and tumor growth.
Researchers have discovered that slow-growing brain cancer stem cells are resistant to treatment and can survive stress by producing a protein called Abcg1. The study suggests that using different drugs and higher dosages may be necessary to target these treatment-resistant stem cells.
Researchers developed a test to identify women with triple-negative breast cancer, a form of disease difficult to treat. The test assesses gene activity in breast cancer cells, finding those resembling adult stem cells are more likely to spread and recur.
Researchers at the University of Manchester have discovered that graphene oxide can selectively target and neutralize cancer stem cells (CSCs), which are responsible for cancer spread and recurrence. The study suggests that graphene oxide could be used as a non-toxic anti-cancer agent in combination with existing treatments.
Researchers Weissman and Massagué win prestigious prize for their groundbreaking work on cancer stem cells and metastatic spread. Their research aims to develop targeted treatments by understanding the connection between cancer stem cells and immune system control.
Researchers found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The study demonstrates the use of nanotechnology to repurpose existing chemotherapy drugs as effective agents against chemoresistant cancer stem cells.
A recent study by Johns Hopkins Medicine reveals that random mutations during stem cell divisions significantly contribute to cancer risk, accounting for approximately two-thirds of the variation. This finding emphasizes the importance of primary prevention strategies, such as lifestyle changes and eliminating environmental factors.
A University of Colorado Cancer Center study reveals that reprogramming damaged stem cells can prevent cancer after full-body radiation. The research suggests that genetic inhibition of the C/EBPA gene allows healthy stem cells to dominate the blood cell production system, reducing the risk of leukemia.
Researchers found that cancer stem cells regrow and respond to chemotherapy-induced damage by releasing prostaglandin E2, leading to therapy resistance. Blocking PGE2 could potentially enhance therapeutic response, offering a promising new treatment for bladder cancer.
A new study challenges the prevailing view of how bowel cancer develops in the large intestine. Cancer Research UK scientists discovered that faulty genes can cause normal cells to behave like immortal stem cells, leading to tumour formation.
A new drug called Bozepinib has been successfully tested against cancerogenic stem cells in mice, proving its efficacy in inhibiting tumor growth and metastasis. Researchers are now conducting safety tests before running the drug on actual patients.
Researchers discovered that mitochondria are crucial for the survival of cancer stem cells and found sixty-two mitochondrial-related proteins showing increased levels. The study suggests new avenues for treatment by restricting cancer's ability to come back after treatment using MCT inhibitors.
Researchers have identified a key role for the FAK molecule in controlling breast cancer stem cell survival and predicting disease recurrence. Blocking FAK activity with a new drug significantly improved treatment outcomes, suggesting a potential method to predict which patients are most likely to experience recurrence.
Harvard Stem Cell Institute scientists have developed a way to use stem cells in the fight against brain cancer. They genetically engineered stem cells to produce and secrete tumor-killing toxins, which were shown to kill cancer cells in mouse brains. This method solves the delivery issue that led to previous clinical trial failures.
Researchers have challenged conventional thinking on bowel cancer development, proposing a new mechanism involving crypt-generating stem cells. The study found that these stem cells are responsible for maintaining and regenerating the 'crypts' in the bowel lining, and their dysfunction may lead to precancerous and cancerous growths.
Researchers from CNIO have identified a new marker for cancer stem cells using riboflavin, a pigment that emits green fluorescence. This discovery enables the tracking of cancer stem cells in tumors, which are responsible for chemical resistance and tumor growth.
Researchers found that the protein BRD4 plays a crucial role in regulating stem cell identity, holding promise for regenerating tissues and organs. The study suggests that inhibiting BRD4 could be used to reprogram stem cells into specific cell types, such as neurons.
Researchers from CU School of Medicine and Taiga Biotechnologies have discovered a way to expand production of stem cells used to treat cancer patients. This breakthrough technology could also be used to treat inborn immunodeficiency conditions, metabolic diseases, and autoimmune disorders.
Researchers at Queen Mary University of London have uncovered the behavior of stem cells in the human bowel for the first time. They found that within a healthy bowel, only a certain number of stem cells can exist within one area at a time, and increased competition for survival is seen in early tumours.
Researchers at McGill University have identified SUMO1 as a key player in the proliferation of glioblastoma tumour cells. The study reveals that sumoylation of CDK6 protein stabilizes it, enabling cancer stem cell growth and progression. This breakthrough could lead to targeted therapies for treating brain cancer.
A new review article suggests that embryonic and induced pluripotent stem cells are not the only source of all three germ layers in the human body. Adult pluripotent stem cells are located throughout the body and can become every tissue, provided they receive the right instructions.
OMP-54F28, a Wnt inhibitor targeting cancer stem cells, has shown promising results in a Phase I clinical trial. The drug was generally well-tolerated and resulted in stable disease for over six months in several patients with advanced solid tumors.
Researchers developed herpes-loaded stem cells that significantly improved survival rates in mice with glioblastoma multiforme when applied to tumors. The treatment used mesenchymal stem cells as drug delivery vehicles, allowing oncolytic viruses to replicate and kill residual cancer cells.
A team of scientists has identified cancer stem cells in patients with myelodysplastic syndromes, a malignant blood condition that frequently develops into acute myeloid leukemia. The study provides conclusive evidence for the existence of cancer stem cells and suggests that targeting these cells could lead to effective treatment.
Leading scientists from the U.S., Canada, and Belgium discussed cancer stem cells, highlighting their challenges in targeted cancer treatments. The symposium aimed to spark productive dialogues among researchers attending, according to Paul Frenette, director and chair of Einstein's Stem Cell Institute.
Researchers discovered that a subset of immune cells called Th22 acts as a tumor helper, supporting colon cancer cells in renewing and developing stem cell properties. The study suggests targeting the pathway involving epigenetic factor DOT1L to potentially treat colon cancer.
Researchers at Mount Sinai identified a new technique to expand hematopoietic stem cells in cord blood, making them more useful for adult patients. This study has important implications for patients battling blood cancers and the success of life-saving stem cell transplants.
A new study by University of Western Ontario researchers reveals that specific interactions between breast cancer stem cells and lung-derived proteins contribute to lung metastasis. Understanding this phenomenon could lead to improved treatment options for breast cancer patients.
Researchers at National University of Singapore identify cancer-specific stem cell causing gastric cancer, opening possibility of developing new drugs to treat this disease. They discovered a cancer-specific variant of a cell surface protein, CD44v8-10, marks gastric cancer stem cells but not normal cells.
Silibinin from milk thistle extract reduces self-renewal of colorectal cancer stem cells, affecting cell signaling associated with inflammation. The compound also decreases levels of CSC self-renewal-promoting mRNAs.
Researchers have successfully identified two chemical compounds that can maintain functional human leukemic stem cells alive for at least seven days in vitro. This major breakthrough paves the way for the development of new cancer drugs to fight acute myeloid leukemia, a form of blood cancer.
Researchers found that MicroRNA-34 can suppress prostate cancer when paired with p53, but not individually. The study used mice models and found that combined silencing of miR-34 and p53 led to uncontrolled stem cell growth and high levels of cancer.
Penn researchers found that nuclear stiffness, controlled by lamin-A, affects cell migration and survival. Softer nuclei are more susceptible to DNA damage, leading to cell death, while stiffer nuclei allow for easier migration but compromise DNA protection.